Effects of Obesity on COPD

NCT ID: NCT06474858

Last Updated: 2024-06-26

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 166 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2016-09-01

Brief Summary

The purpose of this study is to investigate whether obese COPD patients experience more or less discomfort in daily life. Furthermore the investigators will evaluate if body composition or body fat distribution has effects on symptoms and performance.

Detailed Description

Chronic Obstructive Pulmonary Disease (COPD) and Obesity are two major health problems. The prevalence of both is growing and there is a complex interaction between COPD and obesity. On the one hand obesity impairs lung function, with decreasing static lung volumes being the most significant effect. On the other hand there seems a beneficial role of obesity on lung function in COPD patients. This is because obese COPD patients tend to have less hyperinflation than non-obese COPD patients . An interesting question is what the net effect of these changes in lung function is on respiratory symptoms and quality of life.

In this observational study, the investigators will compare obese and non-obese COPD patients. Pulmonary function, dyspnea and quality of life will be compared between the two groups.

Conditions

COPD; Obesity; Chronic Obstructive Pulmonary Disease

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Normal weight

COPD patients with BMI 18.5-24.99

No interventions assigned to this group

Obese

COPD patients with BMI ≥ 30

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Diagnosed with COPD by a Pulmonologist defined as an obstructive lung function test with FEV1/FVC < 0.7 and FEV1 < 80% predicted
• No exacerbation of COPD at time of inclusion
• Age > 18 years
• Able to perform lung function tests and fill in the questionnaires.

Exclusion Criteria

• Not able to perform lung function tests or fill in the questionnaires
• Diagnosis of Asthma
• Diagnosis of neuromuscular disease
• Diagnosis of heart failure
• Treatment for lung Malignancy in the past
• Active Malignancy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Rijnstate Hospital

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Safir Zewari, MD

Role: PRINCIPAL_INVESTIGATOR

Rijnstate Hospital, Arnhem, The Netherlands

Locations

Department Of Pulmonology, Rijnstate Hospital, The Netherlands

Arnhem, , Netherlands

Countries

Netherlands

Other Identifiers

2014/113

Identifier Type: -

Identifier Source: org_study_id